Influence of CYP2C19*2 Polymorphism on Clinical Outcomes in Moldova’s Patients Treated with Clopidogrel After Percutaneous Coronary Intervention
- 12 September 2023
- book chapter
- Published by Springer Nature
- p. 528-536
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Asociación del polimorfismo CYP2C19*2 con resistencia a clopidogrel en pacientes con alto riesgo cardiovascular en el noreste de MéxicoArchivos de Cardiología de México, 2020
- 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromesEuropean Heart Journal, 2019
- Platelet reactivity patterns in patients treated with dual antiplatelet therapyEuropean Journal of Clinical Investigation, 2019
- Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016JAMA Internal Medicine, 2018
- Pharmacogenetics of ClopidogrelCirculation: Cardiovascular Genetics, 2016
- Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary interventionEuropean Heart Journal, 2015
- Clinical Pharmacokinetics and Pharmacodynamics of ClopidogrelClinical Pharmacokinetics, 2015
- Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjectsArchives of Cardiovascular Diseases, 2013
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 UpdateClinical Pharmacology & Therapeutics, 2013
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009